1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels
2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components
3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage
4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors
5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure
6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion
7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema
8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites
9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement
11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print]
12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print]
13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form
14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines
15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing
16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms
17. On the hydrolytic behavior of tinidazole, metronidazole,
[更多]
渝公网安备 50010802001068号
